Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
McKinsey
McKesson
Boehringer Ingelheim
Colorcon

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

MYOBLOC Drug Profile

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for MYOBLOC

Identify potential brand extensions & biosimilar entrants

SponsorPhase
US WorldMeds LLCPhase 2/Phase 3
St Joseph University, Beirut, LebanonPhase 4
VA Connecticut Healthcare SystemPhase 1

See all MYOBLOC clinical trials

Recent Litigation for MYOBLOC

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Halozyme, Inc. v. Lee2016-12-19

See all MYOBLOC litigation

Pharmacology for MYOBLOC

Company Disclosures: US Patents for MYOBLOC

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08   Start Trial Allergan, Inc. (Irvine, CA) 2013-06-10 RX company
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for MYOBLOC

These patents were identified by searching patent claims

Supplementary Protection Certificates for MYOBLOC

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
300822 Netherlands   Start Trial PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
CR 2016 00031 Denmark   Start Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
PA2015031 Lithuania   Start Trial PRODUCT NAME: TRASTUZUMABAS IR REKOMBINANTINE ZMOGAUS HIALURONIDAZE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
122008000043 Germany   Start Trial PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531
122008000042 Germany   Start Trial PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531
122016000049 Germany   Start Trial PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
93138 Luxembourg   Start Trial PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Moodys
Harvard Business School
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.